Big Drugmakers Are Clinching Smaller Deals
Wall Street Journal
J&J, Merck and others are focusing on targets costing $5 billion or less, curtailing pricier acquisitions to help smooth regulatory approvals.
https://www.wsj.com/articles/big-drugmakers-are-clinching-smaller-deals-0c039593